BNTX

BNTX

USD

BioNTech SE American Depositary Share

$104.780+0.460 (0.441%)

Real-time Price

Healthcare
Biotechnology
Germany

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$104.320

High

$107.000

Low

$104.215

Volume

0.13M

Company Fundamentals

Market Cap

25.2B

Industry

Biotechnology

Country

Germany

Trading Stats

Avg Volume

0.85M

Exchange

NMS

Currency

USD

52-Week Range

Low $81.2Current $104.780High $129.27

Related News

Analyst Upgrades

HC Wainwright & Co. Maintains Buy on BioNTech, Raises Price Target to $140

HC Wainwright & Co. analyst Robert Burns maintains BioNTech with a Buy and raises the price target from $136 to $140.

View more
HC Wainwright & Co. Maintains Buy on BioNTech, Raises Price Target to $140
GlobeNewswire

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full continuum of cancer from early to late disease stagesDemonstrated encouraging

View more
BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update
GlobeNewswire

BioNTech to Host Innovation Series R&D Day on November 11, 2025

MAINZ, Germany, October 28, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")), will host an edition of the Company's Innovation Series R&D Day at 09:00 a.m. Eastern Standard Time (3:00

View more
BioNTech to Host Innovation Series R&D Day on November 11, 2025
GlobeNewswire

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

MAINZ, Germany, October 27, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the third quarter 2025 on Monday, November 3, 2025. Additionally, the

View more
BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025
Analyst Upgrades

JP Morgan Maintains Neutral on BioNTech, Lowers Price Target to $120

JP Morgan analyst Jessica Fye maintains BioNTech with a Neutral and lowers the price target from $121 to $120.

View more
JP Morgan Maintains Neutral on BioNTech, Lowers Price Target to $120
GlobeNewswire

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Acquisition aims to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech's next milestone in the execution of its oncology